Merck Sharp + Dohme Corp.

Other

Pawan Dhondi

Anandan Palani

Xianhai Huang

Jun Qin

Robert G Aslanian

William J Greenlee

Hubert B Josien

Robert D Mazzola, Jr

Purakkattle J Biju

Wei Zhou

Zhaoning Zhu

Duane A Burnett

Dong Xiao

Kevin D McCormick

Hongjun Zhang

Younong Yu

Phieng Siliphaivanh

Joey Lee Methot

Christopher W Boyce

Ashwin Umesh Rao

Qin Jiang

Chad E Bennett

Xiaohong Zhu

Elizabeth Helen Kelley

Li Dong

Troy McCracken

Jolicia Polivina Gauuan

Andrew J Leyhane

Tesfaye Biftu

Ravi P Nargund

Brian Alexander McKittrick

John W Clader

Qun Dang

Steven L Colletti

Malcolm Maccoss

Cheng Zhu

Dmitri A Pissarnitski

Hongmei Li

Xiao Chen

De-Yi Yang

Zhong-Yue Sun

John P Caldwell

Haiqun Tang

Zhiqiang Zhao

Ruo Xu

Anilkumar G Nair

Xiaoxiang Liu

Thomas A Bara

Salem Fevrier

Henry M Vaccaro

Mihirbaran Mandal

Nam Fung Kar

Ning Shao

Rachel Nicola MacCoss

Candido Gude

Jie Wu

Sylvia Joanna Degrado

William Colby Brown

David James Cole

Monica L Vicarel

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic tricyclic compounds

The invention provides certain quinoxalines and aza-quinoxalines of the Formula (I), and their pharmaceutically acceptable salts, wherein J, J, R, R, R, R, R, R, R, R, X, Y, b, n, and q are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTHfunction. 

[object Object]

This application provides for compounds of the formula Formula I or a pharmaceutically acceptable salt thereof, wherein the individual variables are defined herein, as well as processes to prepare these compounds, pharmaceutical compositions comprising the same and their use in treating disease state associated with the CRTHreceptor. 

In its many embodiments, the present invention provides a novel class of heterocyclic compounds of the formula: as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more disease associated with the central nervous system using such compounds or pharmaceutical compostions. 

Gamma secretase modulators

This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's Disease using the compounds of formula (I).

This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula (I) wherein Ris a fused bicyclic ring of the formula (II). Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I). 

Growing community of inventors

Elizabeth, NJ, United States of America

Pawan Dhondi